Primary care-based multifaceted, interdisciplinary medical educational intervention for patients with systolic heart failure: lessons learned from a cluster randomised controlled trial by Peters-Klimm, Frank et al.
BioMed  Central
Page 1 of 16
(page number not for citation purposes)
Trials
Open Access Research
Primary care-based multifaceted, interdisciplinary medical 
educational intervention for patients with systolic heart failure: 
lessons learned from a cluster randomised controlled trial
Frank Peters-Klimm*1, Stephen Campbell1,3, Thomas Müller-Tasch2, 
Dieter Schellberg2, Goetz Gelbrich4, Wolfgang Herzog2 and 
Joachim Szecsenyi1
Address: 1Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany, 2Department of 
Psychosomatic and General Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany, 3National Primary Care Research and 
Development Centre, University of Manchester, Manchester, UK and 4Coordination Center for Clinical Trials, University of Leipzig, Leipzig, 
Germany
Email: Frank Peters-Klimm* - frank.peters@med.uni-heidelberg.de; Stephen Campbell - stephen.campbell@manchester.ac.uk; Thomas Müller-
Tasch - thomas.mueller-tasch@med.uni-heidelberg.de; Dieter Schellberg - dieter.schellberg@med.uni-heidelberg.de; 
Goetz Gelbrich - goetz.gelbrich@kksl.uni-leipzig.de; Wolfgang Herzog - wolfgang.herzog@med.uni-heidelberg.de; 
Joachim Szecsenyi - joachim.szecsenyi@med.uni-heidelberg.de
* Corresponding author    
Abstract
Background:  Chronic (systolic) heart failure (CHF) is a common and disabling condition.
Adherence to evidence-based guidelines in primary care has been shown to improve health
outcomes. The aim was to explore the impact of a multidisciplinary educational intervention for
general practitioners (GPs) (Train the trainer = TTT) on patient and performance outcomes.
Methods: This paper presents the key findings from the trial and discusses the lessons learned
during the implementation of the TTT trial. Primary care practices were randomly assigned to the
TTT intervention or to the control group. 37 GPs (18 TTT, 19 control) were randomised and 168
patients diagnosed with ascertained CHF (91 TTT, 77 control) were enrolled. GPs in the
intervention group attended four meetings addressing clinical practice guidelines and
pharmacotherapy feedback. The primary outcome was patient self-reported quality of life at seven
months, using the SF-36 Physical Functioning scale. Secondary outcomes included other SF-36
scales, the Kansas City Cardiomyopathy Questionnaire (KCCQ), total mortality, heart failure
hospital admissions, prescribing, depressive disorders (PHQ-9), behavioural change (European
Heart Failure Self-Care Behaviour Scale), patient-perceived quality of care (EUROPEP) and
improvement of heart failure using NT-proBNP-levels. Because recruitment targets were not
achieved an exploratory analysis was conducted.
Results: There was high baseline achievement in both groups for many outcomes. At seven
months, there were no significant mean difference between groups for the primary outcome
measure (-3.3, 95%CI -9.7 to 3.1, p = 0.30). The only difference in secondary outcomes related to
the prescribing of aldosterone antagonists by GPs in the intervention group, with significant
between group differences at follow-up (42 vs. 24%, adjusted OR = 4.0, 95%CI 1.2–13; p = 0.02).
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Conclusion: The intervention did not change the primary outcome or most secondary outcomes.
Recruitment targets were not achieved and the under-recruitment of practices and patients
alongside a selection bias of participating GPs, prohibit definite conclusions, but the CI indicates a
non-effectiveness of the intervention in this sample. We describe the lessons learned from
conducting the trial for the future planning and conduct of confirmatory trials in primary care.
Trial registration: ISRCTN08601529.
Background
Chronic (systolic) heart failure (CHF) is a "common, dis-
abling, deadly, and costly disease" often resulting in hos-
pital admissions with a prevalence rate of approximately
1% in Germany[1,2]. New treatments and care strategies
tend to focus on the prevention of hospital admissions
and improving prognosis. The adherence of physicians to
clinical practice guidelines (CPG)[3] and patients to treat-
ment regimens [4], have been found to be predictors of
better patient outcomes[5]. However, there are barriers[6]
that must be overcome in order to ensure adequate com-
munication between physicians and patients[7] and in
the delivery of evidence-based care [8-10]. Furthermore,
deteriorating CHF is associated with decreasing quality of
life (QoL)[11,12]. Studies suggest that QoL is predictive of
the course of CHF, independent of established somatic
predictors of prognosis (such as the left ventricular ejec-
tion fraction)[12,13]. Increasing evidence shows that psy-
chological comorbidities also determine QoL in patients
with CHF[14].
In recent years, strategies designed to translate this evi-
dence in to practice have consisted of changes in the
organisation, delivery and specialisation of care by trained
nurses[15], pharmacists[16], and call-centres providing
home-based or telephone support or telemedicine [17-
19]. These studies have primarily been conducted in a
post-discharge setting and addressed the importance of
adherence, recognising and acting upon deteriorating
symptoms and optimising established pharmacological
treatments.
The majority of CHF patients have contact with General
Practitioners. However, the evidence for the effectiveness
and efficiency of general practice based clinical practice
guidelines is limited [20-22]. Combinations of interven-
tions seem most promising[23], along with evidence-
based educational strategies for physicians[24,25]. How-
ever, interventions that are designed to change GP behav-
iour must be realistic in terms of the effects of educational
strategies on GP knowledge during their careers[26].
The purpose of this study was to develop an educational
model for GPs for the management of CHF and to evalu-
ate it as randomised controlled trial. The original aim was
to conduct a confirmatory trial. However, under-recruit-
ment of participants meant that we conducted an explor-
atory trial of a complex intervention combining
educational sessions with medication feedback. This
paper reports the main findings from the trial and focuses
upon the lessons learned from its planning and conduct.
Methods
Participants – Recruitment and Assignment
In a single mail-out, we invited GPs from the region of
Northern Baden, Germany, to participate in the study.
GPs were eligible for participation if they were certified as
a GP and practised as a SHI (statutory health insurance)-
affiliated physician. GPs were excluded if they provided
unconventional therapies or provided specialist services
(e.g. HIV-therapy).
GPs were expected to recruit an average of 7–8 patients in
to the study. GPs received a screening algorithm for case
finding using electronic medical records. Eligible patients
were adults (aged over 40 years) with objective left- or biv-
entricular heart failure, NYHA functional class II-IV, with
ascertained ejection fraction of 40% or less (e.g. by
echocardiography), with stable symptoms at the time of
inclusion, and diagnosis of a chronic, irreversible CHF at
least 3 months prior to inclusion. We excluded patients
with primary valvular heart diseases and relevant hemo-
dynamic effects, hypertrophic obstructive/restrictive car-
diomyopathy (HOCM/RCM), and people with a
concomitant terminal illness, dementia or severe psycho-
logical illness. We obtained informed consent from all
participants.
After recruitment of practices and patients, stratified ran-
domisation of practices was carried out by an external
third party using the "single-coin method" based on a
computer generated list. The third party stratified practices
according to the number of participating patients per
practice. Intervention allocations were concealed from
particpating GPs and the intervention team by the third
party until shortly before the intervention started in Octo-
ber 2005.
Intervention
We conducted a focus group with 13 GPs who were not
actively participating in the TTT study. The content of the
educational sessions was based on the discussions of thisTrials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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focus group. Both educational interventions were based
on predefined learning targets relevant to heart failure
including psychosomatic aspects (comorbid depression
and anxiety disorders, quality of life, and compliance).
We focused on the optimisation of evidence-based phar-
macotherapy and the detection of depressive comorbid
disorders in patients with CHF. The intervention team
consisted of one GP, one cardiologist and one specialist in
psychosomatic medicine. The new intervention group
(Train the trainer = TTT) participated in a multidiscipli-
nary, andragogic (e.g. inputs of theoretical knowledge
with group work in "sandwich technique"), and didactic
(e.g. problem-based learning) training course including
elements of specific knowledge (e.g. CPG content), com-
munication skills (standardised patients with video obser-
vation and peer feedback), detection and management of
comorbid mental disorders (diagnostic properties of
screening tools) as well as organisation of the practice in
order to implement newly acquired knowledge ("my plan
for my practice"). For the same reason, structured case-dis-
cussions were held on real patients. The interventions are
depicted in Figure 1, as recently recommended[27]. Addi-
tionally, GPs in the TTT group received medication feed-
back for individual patients participating in the study
(data from baseline documentation of patients). The
existing percentage of patients receiving the target dose of
ACE-inhibitors (or angiotensin-II receptor antagonists)
and beta-blockers was calculated using current guidelines
as shown previously and printed out as a graphical depic-
tion for each patient[28].
GPs from the control group received a single three-hour
lecture by a senior cardiologist with extensive didactic
expertise based on the aforementioned predefined learn-
ing targets.
Masking
The nature of the intervention entailed that participating
physicians and individuals of the intervention team were
unblinded, while patients were not informed about group
assignment. No interim analyses were conducted during
the observation period, with the exception of data collec-
tion on heart failure medication for pharmacotherapy
feedback. Neither the study statisticians nor the data mon-
itoring committee saw unblinded data or had any form of
contact with study participants.
Objectives
We investigated whether the intervention would improve
health-related quality of life (QoL), reduce hospital
admissions or mortality, improve self care behaviour,
improve satisfaction with provided care and improve dis-
ease course in patients with CHF. Compared with the con-
trol group, we hypothesised that the new intervention
would result in an improvement in QoL (SF-36, Physical
Functioning scale) of at least 6.6 points.
Outcomes
The primary outcome was self-assessed quality of life at
follow-up at seven months, i.e. Subscale 1 (Physical Func-
tioning) of the German version of the SF-36[29,30] (a
generic, multidimensional instrument). Secondary out-
comes included further SF-36 subscales, the German ver-
sion of the Kansas City Cardiomyopathy Questionnaire
(KCCQ)[31] (a disease-specific instrument) (KCCQ-os).
A mean five-point change in the scales of the SF-36[30,32]
and in the overall summary score (KCCQ-os)[33] repre-
sents a clinically significant difference. Further pre-speci-
fied secondary outcomes were total mortality or heart
failure hospital admissions, depressive disorders meas-
ured using the PHQ-9[34,35], the European Heart Failure
Self-Care Behaviour Scale (EHFScBS)[36], patient-per-
ceived quality of care (EUROPEP)[37], and improvement
of heart failure according to NT-proBNP-levels[38,39].
Data collection
The trial was part of the Competence Network of Heart
Failure and conducted as a clinical trial according to the
principles of ICH/GCP (for example: a list of involved
study personnel, screening of eligible patients, informed
consent, registration and pseudonymisation of
patients)[40]. GPs received an initiation visit by a study
nurse, which included an introduction to the trial's inves-
tigator file. GPs collected and documented clinical data
(history, current clinical status), laboratory results, ECG,
detailed medication etc., discontinuation of the study by
the patient, and mortality data on pre-specified case
report forms according to the Basic Clinical Dataset
(BCD) of the Competence Network of Heart Failure a
nationwide interdisciplinary research project involving
medical doctors and scientists from university and other
clinics, research institutes, heart centers, medical practices
as well as organisations, associations and industry http://
www.knhi.de[41]. This network aims to obtain an addi-
tional value for patients, clinicians and scientists by mul-
tidimensional connection of these numerous partners by
conducting – amongst others – clinical trials). They also
took blood samples for the determination of NT-proBNP
at baseline and follow-up. NT-proBNP was measured
using the Elecsys 2010 analyser from Roche Diagnostics,
Germany. GPs also documented the number of practice
visits by patients, referrals to a cardiologist, and hospital
admissions.
Sample size calculation
For the primary outcome, we took into account the
expected small effect of the intervention and the natural
deterioration of QoL, esp. in the scale physical function-
ing. Therefore, we assumed mean small decline of 3.3
points in the control group due to the natural disease tra-
jectory and a small mean improvement under the inter-
vention by 3.3 points, resulting in the expected net
difference of 6.6 points in QoL in favour of the interven-Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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Graphical depiction of the (i) timeline, (ii) composition and duration (' = minutes), (iii) content and (iiii) educational format (EF)  of the educational interventions; PM = printed material Figure 1
Graphical depiction of the (i) timeline, (ii) composition and duration (' = minutes), (iii) content and (iiii) educa-
tional format (EF) of the educational interventions; PM = printed material. Objects are represented by squares (to 
reflect their fixed nature, e.g. handout of printed material) and activities by circles (to reflect their flexibility, e.g. group work). 
Different components are labelled using different letters.Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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tion. The standard deviation from cross-sectional analyses
is reported to be 23[30]. Using the serial correlation from
baseline to follow-up measurements of 0.6[30], we can
calculate the anticipated variance (SD) of the difference of
423.2 (20.57). Therefore, in a two-sided sample calcula-
tion for 80% power at an α-level of 5%, 154 patients were
needed per arm. To account for the clustered design, the
literature indicated that intra-class correlation coefficients
(ICC = GP variance/[GP variance + patient variance]) of
health outcomes (like QoL) are generally lower than
0.05[42,43]. As the German primary care is characterised
by small, office-based practices, we could expect that each
participating GP would come from another practice. Our
assumption was that the mean change of GP would devi-
ate less than ± 5 points from the overall mean in 95% of
all practices. This results in a SD (Variance) of GP of 2.5
(6.25) and an ICC of 0.015 to account for the variable
responses of GPs and patients to the intervention. Thus,
with k = number of GPs (60), n = sample-size from con-
ventional planning (308), we obtain the total N = k*n*(1-
ICC)/(k-n*ICC) = 329. We anticipated a drop out rate of
30%[2], as a result of which 329 cases would provide 70%
power. Accordingly, 329*10/7 = 470 cases represented
100%. In order to obtain a total sample of 470 patients,
we planned to include 60 practices with 7–8 patients per
practice, assuming a practice prevalence of 1% similar to
the estimated average prevalence in the German popula-
tion[2,44].
Statistical methods
In order to identify group differences in the baseline char-
acteristics of GPs and patients, we used chi-square and t-
tests. For continuous dependent variables (score at fol-
low-up), comparisons between the intervention and con-
trol practices were assessed using linear mixed effects
regression models (SAS 9.1 proc mixed) with the practice
as a random effect nested in groups. These analyses
accounted for the intraclass correlation within each prac-
tice attributable to clustering from randomisation accord-
ing to practice. The analysis model included the fixed
effect group (intervention vs. control), and the covariates
score at baseline, age, sex, and NYHA functional class.
We analysed the effect of the intervention on binary out-
comes using SAS proc glimmix and generalised linear
mixed effects models with a logit link. We analysed the
effect of the intervention on count-data outcomes using
generalised linear mixed effects models with a poisson
link, and accounting for overdispersion. Continuous out-
comes are presented as adjusted mean differences and
binary or count outcomes as adjusted odds-ratios (ORs)
with 95% confidence intervals (CIs).
Results
Participant flow and follow-up
Figure 2 shows the flow of participating practices (=GPs)
and patients through the trial. We approached a total of
750 GPs in a single mail-out in October 2004. 667 did not
respond; 26 were interested, but finally refused to partici-
pate due to work load; and 20 failed to find eligible
patients. 37 GPs ultimately participated. Between March
and September 2005, these GPs screened 17416 patients
for eligibility and ultimately recruited 168 eligible
patients in 37 practices. Following patient recruitment, we
randomised 18 GPs to the TTT group and 17 GPs to the
Standard care group. Both groups displayed similar cluster
sizes. Some recruiting GPs failed to recruit the intended
number of eligible patients. At the participant level, 14
patients were ultimately lost in the TTT group and 13 in
the Standard group (for details see Figure 2). Table 1
shows similar characteristics for GPs in the TTT and Stand-
ard group. Table 2 shows similar baseline characteristics
for participants in the TTT and Standard group [45].
Interventions
Only few participating GPs from TTT sporadically missed
one of the educational sessions, all of which were held at
the University of Heidelberg. The IG (n = 18) was divided
into two subgroups: TTT subgroups (n = 10/n = 8) came
to the educational meetings in October (10/8) and
November 2005 (8/8), and – after new group formation –
in January (7/9) and March (9/8) 2006. The Standard
group (n = 19) attended a lecture in October 2005.
Psychosocial outcomes
Table 3 shows all patient-reported outcomes at baseline
and at seven-month follow-up. These were the scores for
Quality of life (SF36- and KCCQ), Behaviour change (EHF-
ScBs),  Patient satisfaction (EUROPEP), and Comorbid
Depression (PHQ-9).
Somatic and performance outcomes
Mortality or hospital admissions
Mortality data were available for all participants. More
deaths occurred in the TTT group than in the Standard
group (9 vs. 4) (Table 4), although this difference was not
statistically significant (adjusted odds ratio = 2.0, 95%
confidence interval 0.6 to 7.1; P = 0.27). A total of 31
heart failure admissions occurred in the TTT group and 34
in the Standard group (adjusted odds ratio = 0.8, 95%
confidence interval 0.3 to 2.1; P = 0.63). The combined
end point (mortality or heart failure admission) resulted
in 29 cases in the TTT group and 18 cases in the Standard
group. The Poisson model indicated that this difference
between groups was not significant (adjusted odds ratio =
1.4, 95% confidence interval 0.7 to 2.9; P = 0.35).Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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Primary care activity data
Practice attendances by patients and referral rates are
shown in Table 4. There were no statistically significant
differences between the groups. Prescription rates for evi-
dence-based pharmacotherapy at follow-up were high,
e.g. for the combination of an ACE inhibitor or an angi-
otensin-2 receptor antagonist with a β-blocker we found a
rate of 76.5% for the IG and 77.9% for the CG, although
this group difference adjusted for baseline rates (adjusted
odds ratio 0.8, 95% confidence interval 0.2 to 2.9; P =
0.78) was not significant. With a prescription rate of
42.4% for aldosterone antagonists at seven-month fol-
low-up, TTT showed a significantly greater increase than
Standard with a prescription rate of 23.5% (adjusted odds
ratio 4.0, 95% confidence interval 1.2 to 13.0; P = 0.02).
NT-proBNP
Mean NT-proBNP plasma levels (SD) were 2462.5 pg/ml
(2821.5) in TTT (n = 87) and 2732.2 pg/ml (5793.5) in
Standard (n = 69) (Table 4). Mean levels decreased in
both groups. There was a non-significant difference
between the groups (adjusted mean difference for the
transformed levels = 0.17 points, 95% confidence interval
0.04 to 0.39; P = 0.11).
Discussion
Summary of main findings
The low power of the trial due to under-recruitment does
not allow definitive conclusions regarding the effective-
ness of the intervention in terms of the primary outcome
(generic QoL, i.e. scale physical functioning of SF-36), but
failed to show effectiveness in a seven-month follow-up.
The intervention combined multifaceted, interdiscipli-
nary educational sessions with pharmacotherapy feed-
back for GPs and was compared to a control group that
received only a standard lecture. In terms of further
patient-reported outcomes, we found impaired QoL, but
good self-care and a generally high level of satisfaction
Table 1: Baseline characteristics of all 37 participating general practices from Baden-Wuerttemberg. 
Intervention group (n = 18) Control group (n = 19)
Practice factors at baseline
Female GPs 3 (17) 4 (21)
Age of GPs in years (SD) 50 (9.4) 50 (5.9)
Certification of GPs since years (SD) 16 (11.4) 15 (7.2)
No. of GPs (whole time equivalent)
Single 9 (50) 11 (57.9)
Two 8 (44.4) 5 (26.3)
More than two 1 (5.6) 3 (25.8)
Location
Rural 13 (72.2) 9 (47.4)
Suburban 2 (11.1) 4 (21.1)
Urban 3 (16.7) 6 (31.6)
List size (patients per quarter)
0–999 6 (33.3) 3 (15.8)
1000–1499 5 (27.8) 8 (42.1)
>1499 7 (38.9) 7 (36.8)
Participation in disease management programmes or quality circles 17/18 (94.4/100) 19/18 (100/94.7)
Values represent number (percentages) of practices unless stated otherwiseTrials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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Table 2: Baseline comparison of intervention and control group patients (n = 168). 
Intervention group (n = 91) Control group (n = 77)
Male sex 63 (69.2) 53 (68.8)
Mean (SD) age (years) 68.4 (10.6) 69 (9.5)
Living alone 27 (29.4) 22 (28.6)
No information 3 (3.7) 11 (14.3)
Social class*:
Mean (SD) score 8.9 (3.8) 8.8 (4.3)
lower, middle, upper class 46 (52.3), 34 (54),
36 (40.9), 21 (33.3),
6 (6.8)
(n = 88)
8 (12.7)
(n = 63)
NYHA-functional class (according to GP)
II 44 (48.4) 41 (53.3)
III 46 (50.6) 33 (42.9)
IV 1 (1) 3 (3.9)
Mean (SD) LVEF 32.5 (7.1)
(n = 79)
34.4 (6.5)
(n = 64)
Main cause of CHF
CHD 43 (47.3) 31 (40.3)
Cardiomyopathy 29 (31.9) 21 (27.3)
Hypertension 6 (6.6) 15 (19.5)
Not clear 13 (14.3) 10 (13)
Mean (SD) duration (years) of CHF 5.6 (4.9) 5.8 (5.6)
Localisation of CHF
Left 55 (60.4) 50 (64.9)
Left and right 31 (34.1) 24 (31.2)
Unknown 5 (5.5) 3 (3.9)
Cardiovascular interventions
PTCA/Stent (any) 37 (40.7) 19 (24.7)
Bypass (any) 23 (25.3) 20 (26)
Pacemaker (any) 18 (19.8) 13 (16.9)
ICD 19 (20.9) 11 (14.3)
Reanimation/Defibrillation 7 (7.7) 7 (9.1)Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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with care in both groups, with no significant differences or
changes. The intervention led to a significantly higher
increase in the prescription rate of aldosterone antago-
nists and seemed to lead to a concomitant increase in pri-
mary care activity (by increase of practice attendances).
The following discussion is structured along the descrip-
tive and exploratory character of the study and includes
the lessons we have learned from planning and conduct-
ing the trial.
Comparison with existing literature
We compared QoL, self-care, patient satisfaction with care
and performance measured by guideline adherence. Our
study confirms that patients with CHF report impaired
QoL[11]. Trials with a positive impact on the QoL in heart
failure patients, typically use complex and multidiscipli-
Medical conditions
Atrial fibrillation 21 (23.1) 12 (15.6)
PAD 15 (16.5) 14 (18.2)
Cerebrovascular disease 18 (19.8) 14 (18.2)
COPD 18 (19.8) 15 (19.5)
Depression 22 (24.2) 17 (22.1)
Creatinine-Clearance: Mean (SD) GFR (ml/min)** 74.1 (31.7) 66.5 (27.4)
Cardiovascular risk factors
Diabetes mellitus 32 (35.2) 29 (37.7)
Hypertension 68 (74.7) 60 (77.9)
Dyslipidemia 68 (74.7) 60 (77.9)
Hyperuricemia 44 (48.4) 33 (42.9)
(Ex-)smoker
(since at least 6 months)
34/17
(37.4/18.7)
34/9
(44.2/11.7)
Drugs at baseline included:
ACE inhibitor/A2RA 83 (91.2) 68 (88.3)
β-blocker 71 (78.0) 62 (80.5)
ACE inhibitor/A2RA and β-blocker 65 (71.4) 57 (74.3)
Spirononolactone/Eplerenone 29 (31.9) 19 (24.7)
Loop diuretics 55 (60.4) 47 (61)
Cardiac glycosides 32 (35.2) 32 (41.6)
Antidepressants 7 (7.8) 5 (6.5)
Soporifics/hypnotics 7 (7.7) 3 (3.9)
Values represent number (percentages) of patients unless stated otherwise.
*Social Class according to modified German Winkler-index[45] (lower class: 3–7; middle class: 8–14; upper class: 15–21); NYHA, New York Heart 
Association; LVEF, Left ventricular ejection fraction; CHF, Chronic (systolic) heart failure; CHD, Coronary heart disease; PTCA, Percutaneous 
Transluminal Coronary Angioplasty; ICD, implantable cardioverter defibrillator; PAD, Peripheral arterial disease; COPD, Chronic obstructive 
pulmonary disease; ** Estimation of the GFR according to the formula of Cockroft and Gault; ACE = angiotensin converting enzyme; A2RA = 
angiotensin-2 receptor antagonist;
Table 2: Baseline comparison of intervention and control group patients (n = 168).  (Continued)Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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Flow of clusters and participants through the trial Figure 2
Flow of clusters and participants through the trial.
Excluded:
No answer (667 practices), 
Interested, but refused due to high 
time and effort (26 practices), 
Participated, but did not find eligible 
patients (20 practices) 
Clusters:  
 Analysed
  17 practices, median practice size = 6, 
mean 4.7, range 1-9 
 Excluded from analysis 
  One practice with 1 patient who died (1) 
Participants:  
 77 (85%)p articipants analysed
Clusters:  
 Analysed 
  19 practices, median practice size = 2, 
mean 3.6, range 1-8 
Excluded from analysis
  0 practices 
Participants:  
64 (83%)p articipants analysed
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Patients assessed for eligibility by 
37 practices 
(17416)
Excluded (17247) 
Did not meet inclusion criteria (17221),  
Refused to participate (18),  
Did not show up for informed consent (1),  
Did meet inclusion criteria, but doctors 
judged “too malcompliant” (2), 
No information (5)
Lost to follow-up
 0 practices  
 4 participants died, 4 participants    
discontinued intervention 
 5 did not respond to quality of life 
questionnaire (baseline or follow-up) 
Lost to follow-up 
 0 practices  
 9 participants died, 2 participants 
discontinued intervention 
 3 did not respond to quality of life 
questionnaire (baseline or follow-up) 
Randomised
37 practices, 168 participants
Allocated to new intervention  
(18 practices)
Received intervention 
  18 practices, median practice size = 5.5, 
   Mean 5.1, range 1-9 
  91 Participants 
Allocated to standard intervention
 (19 practices)
Received intervention 
19 practices, median practice size = 3,   
   Mean 4.1, range 1-9 
  77 Participants 
Invited to participate (750 
practices)Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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Table 3: Mean generic quality of life (SF-36), disease-specific quality of life (KCCQ), European heart failure self-care behaviour 
scale (EHFScBs), patient satisfaction (EUROPEP) and depression status (PHQ-9-D) scores for groups at baseline and seven-month 
follow-up
Intervention group Control group No ICC
Score (SD) No Score (SD) No Adjusted mean difference** (95% 
CI); p***-value
SF-36 scales*
Physical functioning Baseline 52.2 (27.7) 77 45.5 (27.8) 64
Seven months 44.9 (28.9) 77 43.6 (26.3) 64 141 0 -3.3 (-9.7 to 3.1); 0.30
Role functioning, physical Baseline 42.5 (44.4) 67 34.3 (41.3) 54
Seven months 31.3 (41.5) 75 37.9 (43.5) 60 119 0.12 -5.9 (-19.7 to 7.8); 0.30
Bodily pain Baseline 63.2 (27.9) 76 60.5 (29.5) 64
Seven months 58.5 (29.9) 76 53.8 (29.2) 64 139 0.000 3.6 (-5.6 to 12.7); 0.43
General health perceptions Baseline 48.3 (17.8) 77 44.2 (19.2) 63
Seven months 44.9 (18.6) 74 44.3 (18.2) 64 137 0.000 -2.0 (-7.5 to 3.6); 0.47
Vitality Baseline 43.9 (21.3) 75 43.9 (22.5) 63
Seven months 39.0 (21.3) 77 43.1 (20.4) 63 137 0.070 -4.1 (-11.1 to 2.7); 0.22
Social functioning Baseline 75.3 (23.2) 77 67.3 (27.4) 63
Seven months 64.0 (31.4) 77 64.8 (28.9) 64 140 0.10 -5.6 (-16.8 to 5.6); 0.31
Role functioning, emotional Baseline 65.9 (45.2) 68 66.0 (46.0) 54
Seven months 56.3 (47.0) 71 60.3 (46.5) 58 117 0.000 -2.6 (-18.1 to 12.9); 0.73
Mental health Baseline 62.3 (20.2) 75 66.0 (20.3) 62
Seven months 58.9 (21.7) 77 63.8 (20.0) 63 136 0.002 -1.8 (-8.0 to 4.4); 0.56
KCCQ* overall summary
Baseline 66.7 (20.9) 78 63.6 (20.2) 60 -2.4 (-9.3 to 4.4); 0.47
Seven months 64.0 (23.7) 78 65.3 (20.9) 64
EHFScBs****
Baseline 24.4 (7.8) 90 23.8 (7.5) 70 1.3 (-0.9 to 3.5); 0.24
Seven months 24.1 (7.9) 76 23.6 (6.8) 64
EUROPEP*****
Baseline 105.8 (9.3) 90 106.2 (8.7) 69 -0.5 (-4.1 to 3.2); 0.80Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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nary interventions at the patient level (heart failure pro-
grammes) in a post-discharge setting[46,47]. These
patients were by definition unstable as they were hospital-
ised due to heart failure and more symptomatic ("ill")
with a lower QoL at enrolment, while not necessarily
more "diseased", as indicated by the past medical history
and substantial comorbidities[46,47]. Patients in our trial
were enrolled in primary care and had stable CHF at
enrolment.
Although reporting comorbidity and impaired QoL
scores, our patient sample revealed a higher level of self-
care than previously reported[36]: Mean sum scores of
around 24 (SD: 6.8–7.9) were better than in the sample
from the validation study in which 442 patients from two
centres in Sweden, three in the Netherlands and one in
Italy were included[36]. Mean sum scores were 33.3 (7.8)
vs. 29.6 (9.0) for subgroups extra care vs. standard care
(defined by extra patient education about heart failure).
Data on self-care from a trial testing community pharma-
cists showed similar high ("bad") baseline scores: Mean
(SD) scores were 31.1 (8.7) vs. 30.6 (9.1) at baseline. Self-
care improved in both groups at three and six month's fol-
low-up (26.1 vs. 26.6 and 26.6 vs. 28.3, respectively). An
intensive heart failure programme in a physician-nurse
directed heart failure clinic had better, similar baseline
scores to our sample (23.6 vs. 25.5 for intervention and
control groups). The intervention improved self-care in a
3 months follow up, while scores at 12 months were sim-
ilar as at baseline again. Still, there were significant
between group differences because of worsening self-care
scores in the control group (30.2 at 12 months). This
worsening self-care was not found in our (active) control
group (at 7 months).
The high overall satisfaction with care scores in our sam-
ple are similar to those found in the German sample in a
European comparative patient survey in general practice
using the EUROPEP instrument[37].
Comparable educational interventions in the CME setting
have proven their efficacy in other clinical fields[24,25];
outcomes are typically knowledge or performance based
rather than using patient-related outcomes: For CHF, edu-
cational programmes for GP peer review groups have not
been shown to be beneficial for performance as assessed
by prescription behaviour[48]. Compared with the litera-
ture (from 2002), GPs in our study (2005) showed high
guideline adherence with regard to the prescription of evi-
dence-based pharmacotherapy[8]. Even more recent stud-
ies suggest potential for improvement with regard to
evidence-based pharmacotherapy [48-50], although the
samples in these studies are of minor validity due to a lack
of ascertained left ventricular systolic dysfunction (LVSD)
and therefore not directly comparable. LVSD remains the
crucial indication for prescribing evidence-based pharma-
cotherapy, preferably towards target doses[3,9,51]. There-
fore, a rationale for the TTT-intervention was that patients
with LVSD and a suspected low level of care could benefit
from optimised treatment[3,51]. However, there is still a
Seven months 104.8 (10.4) 77 104.5 (10.8) 63
PHQ-9******
sum score Baseline 7.4 (5.6) 91 7.4 (5.8) 76
Seven months 8.6 (5.9) 77 7.4 (5.4) 63 0.8 (-0.7 to 2.3); 0.30
adjusted odds ratio******* (95% CI); 
p***-value
No. (%) of Major Depressive 
Syndromes
Baseline 12 (15.6) 77 7 (11.1) 63
Seven months 14 (18.2) 77 8 (12.7) 63 1.5 (0.5 to 4.6); 0.48
*High scores imply better health.
**Based on analysis of covariance comparing results at seven-month follow-up.
***Adjusted for baseline score, ICC, New York Heart Association class, gender and age.
****Scores range from 12–60; low scores imply better self-care behaviour.
*****Scores range from 23–115; higher scores imply higher patient satisfaction regarding provided care.
******For details see methods section
*******According to generalised linear mixed effect models with a logit link using SAS proc glimmix to compare the number of outcomes between 
groups
Table 3: Mean generic quality of life (SF-36), disease-specific quality of life (KCCQ), European heart failure self-care behaviour 
scale (EHFScBs), patient satisfaction (EUROPEP) and depression status (PHQ-9-D) scores for groups at baseline and seven-month 
follow-up (Continued)Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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Table 4: Heart failure hospital admissions and total mortality during seven-month trial follow-up, selected prescription rates for 
patients at seven-month trial follow-up, mean NT-proBNP-values at baseline and seven-month follow-up and primary care activity 
data during seven-month trial follow-up
Outcome Time Intervention group Control group
No No
Adjusted odds ratio* (95% CI); p**-
value
Death (any cause) Seven months 9 91 4 77 2.0 (0.6 to 7.1); 0.27
Patients admitted to hospital due to 
heart failure, no. (%)
Seven months 23 (27.1) 85 16 (23.5) 68 1.2 (0.5 to 2.6); 0.67
No. of heart failure hospital 
admissions
Seven months 31 85 34 68 0.8 (0.3 to 2.1); 0.63
Heart failure hospital admission or 
death
Seven months 29 89 18 70 1.4 (0.7 to 2.9); 0.35
No. (%) of drugs 85 68 adjusted odds ratio*** (95% CI); p**-
value
ACE inhibitor or A2RA Seven months 78 (91.8) 61 (89.7) 0.9 (0.2 to 3.4); 0.87
β-blocker Seven months 68 (80) 57 (83.8) 0.7 (0.2 to 2.7); 0.58
ACE inhibitor/A2RA and β-blocker Seven months 65 (76.5) 53 (77.9) 0.8 (0.2 to 2.9); 0.78
Spirononolactone/Eplerenone Seven months 36 (42.4) 16 (23.5) 4.0 (1.2 to 13.0); 0.02
Mean NT-proBNP- values (pg/ml) (SD) Adjusted mean difference**** (95% 
CI); p**-value
Crude Baseline 2462.5 (2821.5) 87 2732.2 (5793.5) 69
Transformed***** 4.3 (1.0) 4.1 (1.1)
Crude Seven months 2031.6 (3575.4) 71 1411.7 (2218.1) 57 0.17 (-0.04 to 0.39); 0.11
Transformed***** 3.9 (1.1) 3.6 (1.1)
Mean practice attendances (SD) Seven months 24.0 (16.0) 80 21.6 (15.3) 67 3.9 (-2.9 to 10.7); 0.25
Mean referrals to cardiologist (SD) Seven months 2.2 (2.5) 85 2.2 (1.9) 68 -0.03 (-0.8 to 0.7); 0.93
*Poisson regression model comparing number of outcomes between groups
**Adjusted for recruitment site (cluster), baseline value, New York Heart Association class, age and gender
***According to generalised linear mixed effect models with a logit link using SAS proc glimmix to compare the number of outcomes between 
groups
****Based on analysis of covariance comparing results at seven–month follow-up
***** Due to a skewed distribution of NT-proBNP, logarithmic transformation was performed. Approximation to a normal density was achieved 
using the formula t = 2*log10(B+10)-2, where B denotes the raw NT-proBNP value[39]Trials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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lack of evidence for the effectiveness of (both non-phar-
macological and pharmacological) treatment of patients
with "undefined" (e.g. diastolic) heart failure ("elderly
female patient in general practice")[52].
In our patient sample, prescription rates of ACE-inhibitors
(or A2RA) and beta-blockers were "already" very high at
baseline, allowing primarily up-titration towards target
doses[28]. This effect of TTT could be shown in a separate,
more detailed analysis on guideline adherence[53]. Gen-
erally, interventions to improve guideline adherence to
the prescription and target dosing of ACE-inhibitors (a
hospital-based intervention) [54] or beta-blockers with
mixed results [55,56] are more successful if they succeed
in professional engagement[55]. The latter was the case in
our tailored intervention.
Strengths and limitations of the study
Internal Validity
The processes of recruiting practices and patients and con-
cealed randomisation, ensured equivalent groups of both
GPs and patients at baseline and there was a good follow-
up rate of patients (84% for the primary outcome). How-
ever, it is not possible to blind GPs to treatment group in
such studies, which may have biased the activity of GPs as
well as patient responses to questionnaires. Originally,
the trial included a follow-up immediately before the
intervention to detect any observer bias (the Hawthorne
effect); we had to amend this design, however, on account
of feasibility and work overload for the documenting GPs.
The insufficient recruitment of participating GPs and
patients with left ventricular systolic dysfunction (LVSD)
meant that we had to turn the trial, and its research ques-
tion concerning the primary endpoint (QoL), into an
exploratory trial.
External validity
We were not able to perform a non-responder analysis,
but we have some indication that our sample of GPs was
highly selective (Table 1): While the participating GPs
were representative in terms of mean age and the number
of GPs in one practice, they also had larger than average
list sizes: the average list size in Germany is approximately
800 patients, and patients are free to change their doctor
at any time. Almost all participating GPs adopted the Ger-
man disease management programmes (average German
participation rate approximately 53% in 2006) and also
actively took part in peer review groups ("quality circles")
(average German participation rate approximately 30% in
2006). Furthermore, a selection bias is supported by a
high guideline-adherence at baseline regarding evidence-
based pharmacotherapy (Table 2).
Meaning of the study – lessons learned
Due to the low power of the study it is only possible to
speculate on the possible reasons for the lack of effective-
ness of the intervention on QoL. We identified the follow-
ing possible reasons:
1. Testing against an unblinded and active control group
hampers proving efficacy but this cannot be changed due
to the nature of complex interventions and ethical consid-
erations.
2. Given the indirect design of our study, with the inter-
vention at the level of the GP and outcome measurement
at the level of the patient, our follow-up may have been set
too early: While all GPs received the TTT-course, our eval-
uation in month 6 showed that GPs had implemented
approximately 30–40% of the self-determined implemen-
tation targets (Figure 1).
3. The intervention may have a (transient or permanent)
negative effect because of up-titration[28,53] of β-block-
ers by GPs might have led to significant (transient) wors-
ening of symptoms such as dyspnoea. Furthermore,
increased activity of GPs in other contexts (including
more scheduled attendances or serum level controls)
could cause patients to perceive that they are more ill than
was previously the case.
4. Our intervention was possibly carried out at a too late
stage in the course of the disease as patients had a mean
history of CHF of approximately six years. Improved
patient outcomes have been shown in newly diagnosed
patients or following a deterioration requiring hospital
admission. Our patient sample shows a higher level of
self-care behaviour than previously shown, suggesting
that the patients in our study had already adapted their
lifestyle to their diagnosis.
Lessons learned
In this trial, we encountered problems administering the
study which we documented systematically along with
possible solutions for how such similar problems could
be dealt with in future studies (see Additional file 1, table
S1).
Regarding the conceptual and planning phase of the trial,
several factors hampered a tailoring the trial to general
practice (see Additional file 1, table S1). The funding was
too small for a clinical trial of this size and a longer inter-
vention timeline, as recommend for complex interven-
tions, could have had more impact[57].
In the operational phase we differentiated between the
recruitment of investigators (GPs) and the recruitment ofTrials 2009, 10:68 http://www.trialsjournal.com/content/10/1/68
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study participants. GPs were recruited from a single region
of Germany (Northern Baden) and we encountered prob-
lems recruiting participants. Moreover, while we tempo-
rarily achieved the recruitment target of 60 GPs 26 GPs
who had expressed an interest ultimately declined. Each
GP was telephoned and asked for their reasons for not
participating and the main reasons cited were the per-
ceived workload and time commitment as well as the
small financial incentive for participation. Extending the
recruitment catchment area would have been a possible
solution but was not feasible. In the UK, working with
practice-based research networks (PBRNs) is considered a
priority by national funding programmes, for example the
Primary care research Network (PCRN) http://
www.ukcrn.org.uk/index/networks/primarycare.html or
the Medical research council general practice research
framework (MRCGPRF) http://www.gprf.mrc.ac.uk/. For
more ambitious research questions, a German PBRN
would offer a valuable solution with regard to the recruit-
ment of practices. However, it would be problematical to
generate a representative sample of practices in such a net-
work.
Case finding was another important barrier to the suffi-
cient recruitment of study patients, as 20 GPs failed to
find any eligible patients despite substantial screening
efforts. The different reasons are listed in table S1 (see
Additional file 1).
The inclusion criterion LVSD was another barrier as was a
lack of understanding of LVSD by GPs (see Additional file
1, table S1). Extending the catchment area of recruitment
and funding for a mobile study echocardiography could
have been potential solutions but were not feasible for
logistical reasons.
Regarding the analysis, our actual ICCs revealed numbers
close to 0, hence an ICC as small as 0.015 was a suffi-
ciently conservative assumption. We additionally found a
low mortality rate (7.7%), and considering the lower total
drop-out rate, a sample size of 390 participants would
have been needed.
Conclusion
Due to considerable under-recruitment, the study was no
longer satisfactorily powered to discover the pre-specified
effect size. However, the observed data resulted in a confi-
dence interval which definitely excludes a difference of 6.6
points in favour of the intervention group. Hence the
study is conclusive in so far that the intended moderate
treatment effect has been significantly refuted. Our study
sample showed selection bias with high performing GPs
with access to specialist care and patients that had adapted
their self-care behaviour. Therefore, the study can be con-
ceptualised as an exploratory trial[53]. The patient out-
come results are valuable for future comparisons and
could also be used for pooling in a meta-analysis.
The lessons learned are that measures implemented to
increase internal validity (clinical trial design) were at the
cost of study power and generalisability. No effective
counter-measure was available at the time of the recruit-
ment phase. For primary care-based clinical trials, our trial
underlines the need for primary care research develop-
ment and the establishment of research networks.
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